2 Growth Stocks With High Return Potential

One healthcare stock and a small-cap weed stock are attractive to growth investors because of their high return potentials.

| More on:
A stock price graph showing growth over time

Image source: Getty Images.

People invest in stocks to grow their money, save for the future, or earn profits. Also, historically, the asset class has delivered the highest returns compared with other financial instruments. Cash is king, but expect negative returns if you keep it idle, especially when you factor in inflation.

The TSX offers excellent choices for growth investors seeking a good return on investment (ROI) in the short term. Usually, the time frame for short goals is within six months to three years. A period beyond three years is considered long-term. Sometimes, long-term goals have short-term goals in them.

Currently, Viemed Healthcare (TSX:VMD)(NASDAQ:VMD) and Fire & Flower (TSX:FAF) have ‘”buy” to “strong buy” ratings from market analysts. They forecast a return potential of between 80% and 120% in one year. You can take advantage and load up on the stocks this month while the share prices are absurdly low.

Major growth segment

Increasing the quality of life of Americans afflicted with respiratory diseases is the primary mission of Viemed Healthcare. This $283.45 million company that provides home medical equipment and home therapy services to patients has been operating since 2006. The respiratory diseases include chronic obstructive pulmonary disease (COPD), chronic respiratory failure, and neuromuscular diseases, among others.

The addressable market is vast, considering the report that says about 25 million Americans suffer from various respiratory diseases. Viemed helps alleviate the growing burden on the U.S. healthcare system by offering home treatment products and services. Moreover, home-based solutions are more cost-effective to patients.

Viemed’s $26.3 million net revenues attributable to the core business in Q2 2021 was a new company record. Management expects to generate $26.8 million to $27.8 million in Q3 2021, which would mean another milestone. Its CEO, Casey Hoyt, said, “We continue to see treating respiratory patients in the home as a major growth segment.”

Market analysts are bullish on Viemed. Their average 12-month price target is $13.12, or an 85% climb from the healthcare stock’s current share price of $7.10.

Best bargain deal

Fire & Flower in the cannabis space is more attractive than the industry leaders based on market analysts’ forecasts. They see a 124.32% upside potential in 12 months compared to 66.15% for Canopy Growth and -3.87 for Aurora Cannabis. Similarly, this small-cap weed stock is a bargain deal at only $0.73 per share.

This $271.69 million independent retailer sells cannabis products and accessories through its retail stores in five provinces in Canada. Alimentation Couche-Tard is a strategic partner. The king of convenience stores has a 22.35% ownership stake which could increase to as much as 50.1% soon.

The technology-powered, adult-use cannabis retailer is nearing the road to profitability, given the top-line results in the first half of 2021. Revenue growth was 69% compared to the same period in 2020. Notably, it was the fifth consecutive quarter of adjusted EBITDA. Management said Fire & Flower’s Hifyre business segment is growing at a rate significantly greater than past quarters.

Superior returns

Viemed Healthcare and Fire & Flower are ideal for growth investors with short-term financial objectives. The finance performance in 2021 has so far been impressive. You have better chances of realizing higher, if not superior, returns as the respective businesses thrive in the post-pandemic world.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Christopher Liew has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends ALIMENTATION COUCHE-TARD INC and Viemed Healthcare Inc.

More on Cannabis Stocks

Worker tags plants at an industrial cannabis operation
Cannabis Stocks

Can Canopy Growth Stock Finally Recover in 2024?

Down 98% from all-time highs, Canopy Growth remains a high-risk investment in 2024 given its weak fundamentals.

Read more »

A close up image of Canadian $20 Dollar bills
Tech Stocks

3 No-Brainer Stocks to Buy With $20 Right Now

These three stocks are easy buys for those who don't have all that much to spend, and want long-term growth…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Slow Burn: Is Aurora Cannabis Finally a Good Buy in June?

One of the benefits of choosing from some of the most beaten-down market segments like cannabis is that even a…

Read more »

Caution, careful
Cannabis Stocks

I Wouldn’t Touch This TSX Stock With a 60-Foot Pole

I wouldn't touch Canopy Growth Corp (TSX:WEED) stock with a 60-foot pole.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why This Little-Known Cannabis Stock Could Double in 2024

This cannabis stock has already doubled this year since 52-week lows and could easily rise that much once more.

Read more »

Bad apple with good apples
Cannabis Stocks

1 TSX Stock I Wouldn’t Touch With a 420-Foot Pole

Down 87% from all-time highs, Cronos Group stock is a still a high-risk investment for long-term shareholders in 2024.

Read more »

A cannabis plant grows.
Cannabis Stocks

Canopy Growth: Buy, Sell, or Hold?

Canopy Growth (TSX:WEED) stock should make a killing on U.S. expansion, but investors will need to be very patient.

Read more »

Marijuana plant and cannabis oil bottles isolated
Energy Stocks

3 Canadian Value Stocks to Buy Right Now

Undervalued Canadian stocks such as Secure Energy should be part of your shopping list in May 2024.

Read more »